Shenzhen Weiguang Biological Products Co (002880) Fair Value & Analysis

Consumer Cyclical · CN · Market cap 37.8B KRW

Analysis

Shenzhen Weiguang Biological Products Co (002880) currently trades at 761.00 KRW, while our model-based Fair Value estimate is 512.35 KRW — implying the stock looks roughly 32.7% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection freeze-dried, lyophilized human rabies vaccine and human prothrombin complex. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 1985 and is based in Shenzhen, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.